Teva Pharmaceutical Industries Market Forecasts & Analysis 2007-2012

Teva Pharmaceutical Industries Market Forecasts & Analysis 2007-2012

“Teva has a robust corporate strategy that should serve it well for years to come, driving strong growth and further innovation. Teva is therefore one of the most exciting and dynamic companies in the global pharmaceutical industry,” finds visiongain report

Just some of the recent headlines surrounding Teva:
- Court rules against Teva in patent dispute – May 11th
- Teva gets tentative ok for generic of Eli Lilly’s Gemzar – May 8th
- Teva Announces Approval and Shipment of Generic Omnicef – May 14th
- Teva loses Merck generics race to U.S. rival Mylan - May 14th

In 2006, Teva Pharmaceutical Industries generated $8408m in net sales worldwide from both innovative branded and generic drugs, firmly establishing itself as a Top-20 international pharmaceutical company and leader in generics. That performance reflects rapid growth in recent years, as represented by a tripling in sales from $2519m in 2002. By 2010, total sales for Teva should reach $13.3bn. These are some of the findings from the ``Teva Pharmaceutical Industries Market Forecasts 2007-2012`` report, published by the business information company visiongain.

Report author Dr Gordon Low said: ``With spectacular sales growth in recent quarters, Teva will raise its profile even higher in the global pharmaceutical sector. Growth will be particularly evident in branded generics and innovative products. In particular, there will be significant developments in NCE development and international business, including further launches of innovative therapeutic molecules later this decade and early in the next.” Stakeholders in the industry therefore cannot afford to ignore developments in Teva.

The purpose of this visiongain report is to examine the commercial prospects for Teva Pharmaceutical Industries in the global healthcare market. Teva is already competing well there, especially in key market segments and developing geographical markets. Its profile as a leading generics and innovation-driven pharmaceutical company will continue to rise. Teva Pharmaceutical Industries 2007-2012, critically examines that company through comprehensive research, market forecasting and qualitative analyses.

Teva’s leading product is Copaxone, for multiple sclerosis, which generated $1414m during 2006. Other revenues are generated from a wide portfolio of generic pharmaceutical products and another innovative drug, Azilect, a treatment for Parkinson’s disease. Teva also produces and markets active pharmaceutical ingredients (APIs) for the industry worldwide.

After its acquisition of generics rival –Ivax Corporation - in a deal finalised in early 2006, Teva achieved overall leadership of the global generics market. Teva clearly has a robust corporate strategy that should serve it well for years to come, driving strong growth and further innovation. Teva is therefore one of the most exciting and dynamic companies in the global pharmaceutical industry, visiongain believes. Consequently, participants in the global market should pay close attention to developments in Teva.

Teva Pharmaceutical Industries 2007-2012 examines that company critically, through comprehensive research and analysis. Importantly, visiongain discusses Teva in the context of the wider pharmaceutical market. This market-based research involved a detailed study of commercial documents, databases, company reports and relevant news. Importantly, visiongain applied techniques such as financial forecasting, SWOT analysis and qualitative projections.

In particular, Teva Pharmaceutical Industries 2007-2012 concentrates on the following essential aspects of that company:
- Detailed analysis of Teva’s divisions and the performance of its products
- Sales forecasts for all Teva’s divisions and the overall group
- Sales forecasts for Teva’s innovative drugs – Copaxone and Azilect
- Discussions of issues affecting the relevant market segments
- Competitor analysis
- Drivers and opportunities for Teva
- Restraints and threats facing the company
- Discussions of corporate strategy in the context of the market
- Strategic alliances and licensing
- International operations
- Pipeline developments and their implications for the future

Leading generics companies such as Teva have established a new paradigm in the generics sector: that of developing innovative drugs. Other international generics companies are in a race to catch up with Teva, the world’s leader in generics and a Top-20 pharmaceutical company in its own right. Teva has already achieved success with its leading innovative product Copaxone. Visiongain predicts that Teva’s sales revenues will continue to rise strongly, as it harnesses opportunities in the expanding generics market and makes further progress as a global discovery-led company.

Unique benefits to you when you order this report
- Full searchable report when you buy the company or corporate editions
- Immediate access through our exclusive Reading Room
- You can access your report whichever country you are in without using harddrive space
- Primary research throughout. You will not find this information anywhere else
- Report stored in your reading room for ever
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables

If you buy one report this year make sure it is the report that will guarantee your success for the forthcoming years. Order this report now.

1 Executive Summary: Teva Pharmaceutical Industries 2007-2012

2 An Introduction to Teva Pharmaceutical Industries
2.1 Teva is a Top 20 Pharmaceutical Company and Global Leader in Generics
2.2 Teva is Listed on Various Stock Exchanges, Including NASDAQ
2.3 Teva Achieved Sales of $8.4bn in 2006
2.3.1 Most of Teva’s Sales are In North America
2.3.2 Most of Teva’s Sales Are Generated by the Pharmaceuticals Division
2.4 Vision and Core Values in Teva
2.5 Human Pharmaceuticals Division
2.5.1 Teva Produces Generic Drugs in All Major Therapeutic Categories
2.5.2 Teva Markets and Develops Innovative Drugs for Specialised Markets
2.5.3 The Pharmaceuticals Division Contributes 90% of Teva’s Revenues
2.5.4 Copaxone (glatiramer acetate)
2.5.5 Azilect (rasagiline)
2.6 Active Pharmaceutical Ingredients (API) Division
2.7 Generic Pharmaceuticals - a Comprehensive Portfolio
2.7.1 Teva USA
2.7.2 Teva Generics in Europe
2.8 Veterinary Products
2.9 Key Acquisitions by Teva
2.9.1 Acquisition of Ivax Corporation in January 2006
2.9.2 Sicor became a wholly owned subsidiary of Teva in January 2004
2.9.3 Acquisition of Novopharm
2.10 A Brief History of Teva
2.10.1 Formation of the Company at the Start of the Twentieth Century
2.10.2 Growth During the WWII and the Establishment of the State of Israel during 1940s & 50s
2.10.3 Consolidation During the 1960s & 70s – Establishment of Teva Pharmaceutical Industries Ltd
2.10.4 Further Acquisitions and Dominance During the 1980s
2.10.5 1990s: Expanding Presence Worldwide
2.11 Key Events in the History of Teva Pharmaceuticals USA

3 Teva Pharmaceutical Industries Is Responding To Challenges and Opportunities in The Market Through Ambitious Corporate Strategy
3.1 The World Pharmaceutical Market Continues to Grow, But Faces Mounting Challenges
3.2 The Continuing Success of International Pharmaceutical Companies is Dependent Upon Important Drivers and Restraints
3.3 Companies Are Gradually Changing Their Strategic Focus to Overcome Challenges in the Worldwide Market
3.4 Reduced Efficiencies in R&D Result in Concerns Over Thinning Pipelines
3.5 Driving and Restraining Forces Acting Upon Teva Pharmaceutical Industries
3.5.1 A SWOT Analysis for Teva Pharmaceutical Industries, 2007-2012
3.6 Teva Has a Focussed Strategy To Cope with Market Conditions and Opportunities
3.6.1 Teva Has Clear Strategic Objectives for the Years Ahead
3.6.2 Strategic Focus Explains Teva’s Recent Growth
3.6.3 Teva is Moving Towards Higher-Value Innovative Molecules
3.7 Teva’s Sales Increased Spectacularly in 2006 after Ivax Acquisition
3.7.1 Ivax Acquisition and Generics Launches Boosted Growth in 2006
3.7.2 All The Principal Geographical Regions Exhibited Strong Growth During 2006
3.7.3 Pharmaceuticals Division was a Strong Driver of Sales Growth in 2006
3.8 Teva Will Increase its Sales Substantially Between 2006 and 2012
3.8.1 From 2007-2012 Sales Will Be Driven By Strong Growth in The Pharmaceuticals Division
3.8.2 Teva Can Remain at the Forefront of the Global Generics Industry and Continue to be a Strong Niche Pharmaceutical Company
3.8.3 Cost Containment in Europe Provides Major Opportunities for Teva
3.9 Teva Reported Strong Results for the First Quarter of 2007
3.10 Generics Companies Such as Teva Must Expand Cautiously, With Valid Strategic Justification
3.10.1 Strategic Vigilance is Required
3.10.2 Generics Companies Use Acquisitions to Access New Markets – With Teva Extending Its Geographic and Technological Reach in That Manner
3.10.3 Teva Has Expanded for Justifiable Strategic Reasons
3.10.4 2007 Will Provide Major Opportunities for Teva, As Will the Period 2010-2012
3.10.5 Teva Recently Expanded Its Manufacturing Facilities in Jerusalem
3.11 Teva Has Benefited from a Vigorous Acquisitions Strategy
3.11.1 Teva Took Advantage of The Hatch-Waxman Act of 1984
3.11.2 Important Acquisitions in Recent Years – Culminating in the Incorporation of Ivax – Have Benefited Teva Immensely
3.11.3 Teva-Ivax Marked the Second Major Generics Acquisition in Recent Times
3.11.4 Differentiation in the Market is Vital to the Continuing Success of Teva – In That Way Teva Can Withstand Downward Pressure On Prices in Conventional Generic Drugs
3.11.5 Incorporation of Ivax in January 2006 Gave Teva Pre-Eminence in the Expanding Global Generics Market
3.11.6 Acquisition of acquisition of Dorom Srl in 2004
3.11.7 Teva and US Company Sicor Signed a Definitive Agreement in 2004
3.11.8 Acquisition of Bayer’s and Merck & Co’s French Generics Units in 2002
3.11.9 2000 Was Marked by Acquisitions of Novopharm and Human Serum & Pharma
3.11.10 Copley Pharmaceutical Institute for Drug Research Acquired in 1999
3.11.11 The 1990s Saw Other Acquisitions by Teva
3.12 Teva Makes Good Use of International Subsidiaries
3.12.1 Most of Teva’s Sales Revenues Are Generated in the US
3.12.2 Europe Also Achieved a Significant Contribution to Revenue
3.12.3 Teva Has Dominance in The US Generics Market After Incorporating Ivax
3.12.4 Significant Global Expansion Since Late 1990s
3.13 In Common With Other Generics Companies, Teva Faces Litigation Over Patent-Related Issues
3.13.1 Paragraph IV Certification
3.13.2 Bayer Filed Lawsuit Against Teva Over Avelox
3.13.3 Teva Provided Update On Litigation Over Generic Celebrex
3.13.4 Agreement With Biovail And Anchen Regarding Generic Wellbutrin XL
3.13.5 Settlement Over Cephalon’s Provigil
3.13.6 Exclusivity for Generic Zocor Not Attained But Strong Revenues for Teva’s Generic Expected
3.13.7 Teva in Litigation with Abbott
3.13.8 Teva Will Continue to Supply Generic Oxycodone Throughout 2007
3.13.9 Teva Filed Patent Infringement Complaints Regarding Sertraline Hydrochloride
3.13.10 Agreement With Pfizer Regarding Idarubicin, Azithromycin, And Epirubicin
3.14 Teva: Collaborations and Licensing
3.14.1 Abitren/Diclofenac Q
3.14.2 Azilect
3.14.3 Budeprion SR
3.14.4 Copaxone
3.14.5 Diltiazem
3.14.6 Nifedipine ER/Nifedipine Teva
3.14.7 Previfem/Tri-Previfem
3.14.8 Purinethol
3.14.9 Purinethol
3.14.10 Quinapril Teva
3.14.11 Verapamil
3.14.12 Zavesca
3.15 ProNeuron Biotechnologies Filed to Annul License Agreement with Teva Over Clinical Trials

4 Pharmaceuticals Division
4.1 The Pharmaceuticals Division Will Yield Strong Growth, Strongly Driving Overall Corporate Revenues
4.1.1 Teva Benefited from an Ambitious Strategy of Acquisition
4.1.2 Teva Had Over 150 Products Awaiting FDA Approval at the End of 2006
4.1.3 Promising First Quarter Results for 2007
4.2 Copaxone – Teva’s First Innovative Drug to Receive FDA Approval
4.2.1 Steady Revenue Increase Expected for Teva’s Flagship Product
4.2.2 Copaxone Faces Present and Future Competitive Challenges in the Market
4.2.3 Copaxone Was Originally Licensed from the Weizmann Institute of Science
4.2.4 Copaxone is the Subject of Promising Clinical Studies
4.2.5 Lifecycle Management of Copaxone: Teva Makes Good Use of Collaborations
4.3 Azilect – Teva’s Recently Launched Innovative Product
4.3.1 Azilect is Currently In a Period of High Early Growth
4.3.2 Azilect is a Potent Agent for Early and Advanced Parkinson’s Disease
4.3.3 Azilect Benefits from Convenient Dosing
4.3.4 Azilect is Co-Marketed in Europe by Lundbeck and Teva
4.3.5 Co-Development of Azilect with Eisai
4.3.6 Phase IV Post-Marketing Study to Investigate Risk of Melanoma
4.3.7 Azilect May Have Potential in the Early Treatment of Parkinson’s
4.3.8 Competition for Azilect
4.3.9 Azilect Has Performed Well in Clinical Studies
4.4 Teva Has a Diverse Generics Portfolio
4.4.1 Revenues from Generics Spread Over Many Products
4.4.2 Teva Receives First US Approval For Generic Uniretic Tablets
4.4.3 Teva Receives Approval For Generic Dostinex Tablets
4.4.4 Teva Announced Approval of Alprazolam ER Tablets
4.4.5 Teva Announced Its Launch of Generic Wellbutrin XL Tablets Through Agreement With Anchen And IMPAX
4.4.6 Teva Announced Tentative Approval Of Sumatriptan Succinate Tablets
4.4.7 Teva Receives Approval for Generic Focalin Tablets
4.4.8 Teva Announced Agreement with Pfizer Regarding Idarubicin, Azithromycin, And Epirubicin
4.4.9 Launch of Generic Zoloft by Teva
4.4.10 Final Approval of Venlafaxine HCL Tablets
4.4.11 Final Approval of Meloxicam Tablets
4.4.12 Tentative Approval of Generic Lotrel
4.4.13 Approval of Generic Zocor
4.4.14 Teva Received First FDA Approval for Generic Proscar Tablets
4.4.15 Tentative Approval of Losartan Potassium & Hydrochlorothiazide Tablets
4.4.16 Tentative Approval for Generic Cozaar Tablets
4.4.17 Tentative Approval of Simvastatin Tablets
4.4.18 Approval of Generic Lexapro Tablets
4.5 The Integration of Ivax’s Operations Greatly Increased Teva’s Strengths in Respiratory Drugs
4.6 Acquisition of Ivax is a Major Coup for Teva
4.6.1 Ivax Acquisition Brought Expertise in Respiratory Field in Particular
4.6.2 As a Condition of the Acquisition, Teva and Ivax Had To Divest Some Products in US Market
4.7 Teva is Active in OTC Products
4.7.1 OTC Products Part of Pharmaceuticals Division
4.7.2 Out-Licensing to Perrigo
4.7.3 Zirtek (cetirizine) Approval Delayed

5 Active Pharmaceutical Ingredients
5.1 Active Pharmaceutical Ingredients Division Will Show Steady Growth, Playing a Supporting Role
5.2 Teva’s API Division is a Major Supplier to the Global Pharmaceutical Industry
5.3 Active Pharmaceutical Ingredients Division Will Benefit from Expanding Global Pharmaceutical Market
5.4 Acquisition of Sicor Brought Valuable Expertise and Capacity in the Production of APIs
5.5 Teva Prides itself on its Technological Capabilities in API Production
5.6 Active Pharmaceutical Ingredients Achieved Similar Growth in Q1 2007 as in Q1 of 2006
5.7 Ivax Acquisition Has Brought Another 30 APIs to Teva’s Portfolio
5.8 Teva’s Expansion into the Japanese API Market in 2006
5.9 Teva Produces APIs Internationally
5.10 Visiongain Concludes that Teva Will Remain at the Forefront of API Supply and Custom Pharmaceutical Manufacturing Throughout the Forecast Period 2007-2012

6 Pipeline Developments in Teva
6.1 Teva is Conducting R&D in Important Therapeutic Areas
6.2 Teva’s Investment in R&D Has Been Rising in Recent Years
6.3 As a Leading Generic Producer Teva Has Progressed into Innovative Research & Development
6.4 Teva Has a Very Strong Generics Pipeline in Addition to Innovative Developments
6.4.1 R&D Focussed on Multiple Sclerosis, Autoimmune Diseases, Neurology and Oncology
6.4.2 Teva R&D is Concentrated in Three Divisions
6.4.3 Generic and Innovative Pipelines Are Strong – Ivax Acquisition Paying Off
6.5 Antineoplastics/Immunomodulating Agents
6.5.1 Stemex Cell Therapy
6.5.2 HMN 214
6.5.3 EDRATIDE (TV 4710)
6.5.4 SAIK-MS
6.5.5 LMB 9
6.5.6 Cervene (TP 38)
6.6 Central Nervous System Agents
6.6.1 Citicoline (IP 302)
6.6.2 Cladribine (NSC 105014F)
6.6.3 Fampridine-SR
6.6.4 Ladostigil
6.6.5 Valrocemide
6.7 Genitourinary System/Sex Hormones
6.8 Respiratory System Agents
6.8.1 Respicort
6.8.2 Other Agents in Development
6.9 Licensing Deal With Vaccinex for Monoclonal Antibody
6.10 Teva Collaborates on Protalix's recombinant plant cell expression technology
6.11 Teva And Procognia (Israel) Ltd. Sign an Exclusive Collaboration Agreement for the Development of Biopharmaceuticals

7 Conclusions
7.1 Teva is a Top-20 Pharmaceutical Company with a Diverse Portfolio of Generic and Innovative Products
7.2 Ivax Acquisition and Generics Launches Boosted Growth in 2006
7.3 Sales in Teva are Dominated by the Pharmaceuticals Division
7.4 From 2007-2012 Sales Will Be Driven By Strong Growth in The Pharmaceuticals Division
7.5 Generic and Innovative Pipelines Are Strong
7.6 Teva Can Remain at the Forefront of the Global Generics Industry and Continue to be a Strong Niche Pharmaceutical Company With Impressive Sales Worldwide

Appendices
Appendix 1: Major Drugs Facing Patent Expiry in the US, 2004-2009
Appendix 2: About Visiongain
Appendix 3: Visiongain Report Evaluation Form


List of Tables
Table 2.1 Top 20 Global Pharmaceutical Companies, 2005
Table 2.2 Teva Net Sales and Income, 2002-2006
Table 2.3 Teva Subsidiaries, 2006
Table 2.4 Sales ($m) by Geographical Area, 2004-2006
Table 2.5 Sales ($m) by Business Division, 2004-2006
Table 2.6 Major Events in Teva USA’s History
Table 3.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 2000-2006
Table 3.2 A SWOT Chart for Teva, 2007-2012
Table 3.3 Teva - Main Financials* ($m), 2005 and 2006
Table 3.4 Sales ($m) by Geographical Region, 2006
Table 3.5 Sales ($m) by Division, 2006
Table 3.6 Teva Sales ($m) by Division and Total Sales, 2006-2012
Table 3.7 Contribution (%) of Total Sales by Division, 2006 and 2012
Table 3.8 Teva Pharmaceutical Sales by Geographical Region and Leading National Markets, June 2005 to June 2006
Table 4.1 Pharmaceuticals Divisional Sales ($m), 2006-2012
Table 4.2 Copaxone and Azilect Sales ($m), 2006-2012
Table 4.3 Copaxone and Azilect Contribution to Sales (%), 2006-2012
Table 4.4 Copaxone Sales ($m), 2006-2012
Table 4.5 Sales ($m), 2006-2012
Table 4.6 Principal Therapeutic Products Manufactured by Teva, 2006
Table 4.7 Teva Pharmaceuticals: Top Five Therapeutic Classes, 2005-2006
Table 4.8 Pharmaceuticals: Leading International Products, 2005-2006
Table 5.1 Active Pharmaceutical Ingredients Divisional Sales ($m), 2006-2012
Table 6.1 R&D Investment by Teva, 2002-2006
Table 6.2 Antineoplastics/Immunomodulating Agents Pipeline
Table 6.3 Central Nervous System Agents
Table 6.4 Genitourinary System/Sex Hormones
Table 6.5 Respiratory System Agents
Table 6.6 Other Agents in Development
Table 7.1 Teva Sales ($m) by Division and Total Sales, 2006-2012


List of Figures
Figure 2.1 Teva Net Sales, 2002-2006
Figure 2.2 Teva Net Income, 2002-2006
Figure 2.3 Sales ($m) by Geographical Area, 2004-2006
Figure 2.4 Sales ($m) by Business Division, 2004-2006
Figure 2.5 Teva Employee Numbers, 2005 & 2006
Figure 3.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 2000-2006
Figure 3.2 Teva - Main Financials* ($m), 2005 and 2006
Figure 3.3 Sales ($m) by Geographical Region, 2006
Figure 3.4 Contribution (%) of Sales by Geographical Region, 2006
Figure 3.5 Sales ($m) by Division, 2006
Figure 3.6 Contribution (%) of Sales by Division, 2006
Figure 3.7 Teva Corporate Sales ($m), 2006-2012
Figure 3.8 Teva Sales ($m) by Division and Total Sales, 2006-2012
Figure 3.9 Sales ($m) by Division and Total Sales ($m), 2006 & 2012
Figure 3.10 Contribution (%) of Total Sales by Division, 2012
Figure 3.11 Teva Pharmaceutical Sales by Geographical Region and Leading Countries, June 2005 to June 2006
Figure 4.1 Pharmaceutical Division Sales ($m), 2006-2012
Figure 4.2 Copaxone and Azilect Sales ($m), 2006-2012
Figure 4.3 Copaxone and Azilect: Relative Contributions (%) to Teva Sales, 2006 and 2012
Figure 4.4 Copaxone Sales ($m), 2006-2012
Figure 4.5 Azilect Revenues ($m), 2006-2012
Figure 5.1 Active Pharmaceutical Ingredients Division Sales ($m), 2006-2012
Figure 6.1 R&D Investment by Teva, 2002-2006Figure 7.1 Teva - Main Financials* ($m), 2005 and 2006
Figure 7.2 Teva Sales ($m) by Division and Total Sales, 2006-2012